EARNINGS AND TRADING: Probiotix flips to profit, eyes "further growth"
The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
----------
DCI Advisors Ltd - British Virgin Islands-based investor in residential resorts in Greece and Cyprus - Nears completion of its sale of Venus Rock Estates in Cyprus, having received the full EUR3.5 million settlement for shares representing the ownership and management rights of Aristo Developers Ltd's Venus Rock Estates Ltd. Notes that it has paid approximately EUR1.8 million in capital gains tax plus interest as assessed by the Cyprus tax authorities, although it is considering lodging an appeal against this assessment. Says the completion of the sale of its remaining indirect 10.68% shareholding in Aristo for the agreed price of EUR6.2 million remains subject to tax clearance in Cyprus. Intends to issue further updates "in due course".
----------
Probiotix Health PLC - Wakefield, England-based life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions - Reports results for the first half of 2026. Revenue jumps 53% to £2.1 million from £1.3 million the year before. Probiotix swings to pretax profit of £79,000 from a £153,000 loss. Notes that its active customer base has grown by more than 15%, reflecting "the growing demand for effective science-backed preventive cardiometabolic supplement products." Also swings to earnings before interest, tax, depreciation and amortisation of £151,000 from a £112,000 loss. Cash balance is £1.2 million as of June 30, against £1.3 million one year prior. Highlights "strong growth in China". "We are pleased with the performance of the business in the first half of the financial year, and the progress we are making...We expect further growth in H2 from APAC and the EMEA regions and going into 2027 through the repositioning of a deeper US offering, expanding sales to include third party distribution and a broadened product positioning to offer LPLDL beyond cholesterol health," comments Chief Executive Officer Steen Andersen.
----------
Ingenta PLC - Oxford, England-based provider of software and services to the publishing industry - Agrees to acquire up to 100% of FirstAida Ltd, with the latter's founder, Dan Brown, joining Ingenta's board as a non-executive director. Ingenta acquires an initial 24.9% equity stake in FirstAida, with consideration to be satisfied through the transfer of 587,930 Ingenta shares and the issue of 210,131 new shares. Company has the option to buy the remaining 75.1% of FirstAida's equity through issuing 2.0 million new shares, "subject to performance targets." The further deferred consideration will be payable six months after the option exercise, if FirstAida's contracted revenue at that point exceeds £500,000. Ingenta will issue 175,000 further new shares for every £200,000 by which the contracted revenue exceeds this amount, up to a maximum of 875,000 shares if contracted revenue passes the £1.5 million mark. Notes that FirstAida's revenue is currently "minimal". Total consideration represents approximately £1.8 million, Ingenta adds. Maximum consideration would represent approximately £2.3 million. "FirstAida has created a suite of AI-based legal software and services which is adjacent to Ingenta's existing IP management suite," the firm says, adding: "What Ingenta does not provide at present is a way for rights holders to effectively investigate cases of potential IP abuse. These complementary services have been created and are being rolled out by FirstAida."
----------
Solvonis Therapeutics PLC - London-based biopharmaceutical company focused on central nervous system disorders - Announces "encouraging results" from an initial in vitro cardiac ion-channel and broader off-target screening of SVN-015 under the US National Institute on Drug Abuse's Addiction Treatment Discovery Program. Says NIDA has confirmed that SVN-015 will advance into further evaluation, following review of the initial screening results. "SVN-015 completed the initial cardiac ion-channel screening and demonstrated an encouraging broader off-target profile," Solvonis explains. Expects the further evaluation to include confirmatory transporter studies and in vivo studies to characterise the onset and duration of SVN-015's pharmacological activity. SVN-015 is Solvonis' proprietary discovery-stage small molecule designed to modulate key monoamine transporters, and is in development as a potential treatment for stimulant use disorder. Solvonis notes: "On the cardiac ion-channel measures assessed to date, SVN-015 demonstrated a more favourable profile than GBR-12909, an earlier dopamine transporter inhibitor evaluated by NIDA as a potential treatment for cocaine dependence and known to interact with several cardiac ion channels." CEO Anthony Tennyson calls the news "an important development milestone for SVN-015," adding: "NIDA's decision to progress SVN-015 provides important external validation of the case for its further evaluation and gives Solvonis access to specialist, non-dilutive preclinical development capabilities."
----------
Copyright 2026 Alliance News Ltd. All Rights Reserved.